Enter inventor name

Ying Li

USPTO Granted Patents = 27 (Patent Applications = 5)

EPO Patents = 10 (Patent Applications = 13)

Average Co-Inventor Count = 5.3

ph-index = 7

Forward Citations = 110(Granted Patents)

Location History:

Springfield, NJ (US) (2014 - 2017)
Millburn, NJ (US) (2016 - 2023)

Company Filing History:

Signal Pharmaceuticals, Inc.

Years Active: 2014-2025

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12343346 - Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same (2025-07-01),

2. 11629153 - Forms and compositions of a MK2 inhibitor (2023-04-18),

3. 11401257 - Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses (2022-08-02),

4. 11241439 - Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same (2022-02-08),

5. 10882867 - Forms and compositions of a MK2 inhibitor (2021-01-05),

6. 10626101 - Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses (2020-04-21),

7. 10604510 - Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[B]azepine-4-carboxami compositions thereof, and uses thereof (2020-03-31),

8. 10596180 - Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl) oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same (2020-03-24),

9. 10463672 - Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same (2019-11-05),

10. 10202364 - Forms and compositions of an ERK inhibitor (2019-02-12),

11. 10189808 - Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses (2019-01-29),

12. 10005760 - Forms and compositions of an ERK inhibitor (2018-06-26),

13. 9969713 - Solid forms of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses (2018-05-15),

14. 9884062 - Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same (2018-02-06),

15. 9827243 - Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one (2017-11-28),

Title: Innovations and Contributions of Ying Li: A Leading Inventor in Pharmaceutical Development

Introduction: Ying Li, an accomplished inventor based in Millburn, NJ, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 26 patents. His innovative research has focused on developing novel compounds and compositions, particularly in the area of MK2 inhibitors.

Latest Patents: Among his latest patents, Ying Li has introduced solid forms of an MK2 inhibitor, which encompass compositions and methods of use. This invention presents a significant advancement in pharmaceuticals by providing solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide. The patent details not only the solid forms but also the methods for their creation and various potential applications.

Career Highlights: Ying Li's career spans prominent roles at leading pharmaceutical companies, including Celgene Corporation and Signal Pharmaceuticals, Inc. His work has had a profound impact, particularly in drug development and innovation.

Collaborations: Throughout his career, Ying has collaborated with esteemed colleagues, including Jean Xu and Benjamin M Cohen. These partnerships have enabled the exchange of ideas and fostered advancements in the pharmaceutical industry.

Conclusion: With 26 patents to his name, Ying Li continues to be a pioneering figure in the world of pharmaceutical innovations. His work on MK2 inhibitors represents just a glimpse of his potential to drive future advancements in the field. As he continues his endeavors, the scientific community eagerly anticipates the next breakthroughs that may emerge from his research.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com